首页 > 最新文献

Seminars in oncology最新文献

英文 中文
Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis. 直肠后囊性火腿肠瘤上的腺癌:一种非常罕见诊断的示意图。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1053/j.seminoncol.2024.10.003
José Felipe Reoyo Pascual, Evelio Alonso Alonso, Lucia Polanco Pérez, Miguel Álvarez Rico

Retrorectal cystic hamartoma (also known as tailgut cyst) is a congenital lesion that originates from debris from the embryonic caudal intestine. Incidentally diagnosed in more than half of cases, the treatment of choice is surgical resection. It is a very rare pathology whose oncological transformation constitutes a true pathological rarity.

直肠后囊性火腿肠瘤(又称尾肠囊肿)是一种先天性病变,源于胚胎尾肠的碎屑。半数以上的病例是偶然确诊的,首选治疗方法是手术切除。这是一种非常罕见的病理现象,其肿瘤转化是真正的病理罕见病。
{"title":"Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis.","authors":"José Felipe Reoyo Pascual, Evelio Alonso Alonso, Lucia Polanco Pérez, Miguel Álvarez Rico","doi":"10.1053/j.seminoncol.2024.10.003","DOIUrl":"10.1053/j.seminoncol.2024.10.003","url":null,"abstract":"<p><p>Retrorectal cystic hamartoma (also known as tailgut cyst) is a congenital lesion that originates from debris from the embryonic caudal intestine. Incidentally diagnosed in more than half of cases, the treatment of choice is surgical resection. It is a very rare pathology whose oncological transformation constitutes a true pathological rarity.</p>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of metformin drug in preventing metabolic syndrome associated with androgen deprivation therapy (ADT) in prostate cancer patients: A systematic review and meta-analysis. 二甲双胍药物在预防前列腺癌患者与雄激素剥夺疗法(ADT)相关的代谢综合征方面的疗效:系统回顾与荟萃分析。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-29 DOI: 10.1053/j.seminoncol.2024.10.001
Ibrahim Abdelnasar Yakout, Mohamed Mustafa Gallab, Daie AbdelRahman Mohamed, Hiba Hamdar, Sara I Ibrahim, Adham Mohamed, Abdelrahman Abdelshafi, Mohamed Abd-ElGawad

Background: Prostate cancer patients undergoing long-term (Androgen deprivation therapy) ADT will tend to have metabolic changes. Metabolic syndrome represents the accumulation of several medical conditions that significantly increase the risk of developing severe diseases like cardiovascular disorders, insulin resistance, and hyperglycemia. We are conducting this systematic review and meta-analysis to fill up the gap and to resolve the debate regarding the effectiveness of metformin in reducing metabolic syndrome associated with ADT in prostate cancer patients.

Methods: We conducted the systematic review and meta-analysis according to the Handbook of Cochrane Systematic Review of Intervention and the PRISMA guidelines. We conducted the search process using the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Scopus, and Web of Science. We selected the articles that fit within the following criteria, Randomized Controlled Trials (RCTs) and Cohort studies which evaluate the efficacy of metformin in reducing metabolic syndromes for prostate cancer patients undergoing androgen deprivation therapy (ADT). The efficacy of metformin in metabolic syndrome that resulted from using androgen deprivation therapy for prostate cancer patients was evaluated by the changes from baseline in Body Mass Index (BMI), waist circumference by cm, glycated hemoglobin (HbA1c), and blood pressure both systolic and diastolic. Revman software Version 5.4.1 was used to perform all statistical analyses.

Results: Our search retrieved 781 records. Seven records were included in our study: 5 published randomized control clinical trials and 2 cohort studies and only 6 studies were included in the meta-analysis. For BMI the pooled effect estimates of 3 studies favored Metformin over placebo, but this is not a significant difference (MD = -0.9, P = 0.05), for systolic pressure the pooled effect estimates of 3 studies favored Metformin over placebo, but this is not a significantly different placebo (MD = -3.18, P = 0.22), for HBA1c the pooled effect estimates of 3 studies showed that no significant difference between placebo and metformin (MD = -0.01, P = 0.86)002E CONCLUSION: Despite the promising direction in some parameters, our findings underscore the need for further research to establish a clearer understanding of metformin's role in mitigating metabolic changes in prostate cancer patients undergoing ADT.

背景:长期接受雄激素剥夺疗法(ADT)的前列腺癌患者往往会出现代谢变化。代谢综合征是多种疾病的累积,会显著增加患心血管疾病、胰岛素抵抗和高血糖等严重疾病的风险。我们正在进行这项系统综述和荟萃分析,以填补空白并解决有关二甲双胍在减少前列腺癌患者 ADT 相关代谢综合征方面的有效性的争论:我们根据《Cochrane 干预系统综述手册》和 PRISMA 指南进行了系统综述和荟萃分析。我们使用以下数据库进行了检索:Cochrane 对照试验中央注册库 (CENTRAL)、PubMed、Scopus 和 Web of Science。我们选择了符合以下标准的文章:随机对照试验(RCT)和队列研究,这些研究评估了二甲双胍对接受雄激素剥夺疗法(ADT)的前列腺癌患者减少代谢综合征的疗效。二甲双胍对前列腺癌患者因使用雄激素剥夺疗法而导致的代谢综合征的疗效是通过体重指数(BMI)、腰围(厘米)、糖化血红蛋白(HbA1c)以及收缩压和舒张压与基线相比的变化来评估的。所有统计分析均使用 Revman 软件 5.4.1 版:我们的搜索共检索到 781 条记录。我们的研究纳入了 7 条记录:5 项已发表的随机对照临床试验和 2 项队列研究,只有 6 项研究被纳入荟萃分析。对于体重指数(BMI),3 项研究的汇总效应估计值显示二甲双胍优于安慰剂,但这并不是一个显著的差异(MD = -0.9,P = 0.05);对于收缩压,3 项研究的汇总效应估计值显示二甲双胍优于安慰剂,但这并不是一个显著的差异(MD = -3.18,P = 0.22),对于 HBA1c,3 项研究的汇集效应估计值显示,安慰剂与二甲双胍之间无显著差异(MD = -0.01,P = 0.86)002E 结论:尽管在某些参数上出现了有希望的方向,但我们的研究结果强调需要进一步研究,以更清楚地了解二甲双胍在缓解接受 ADT 的前列腺癌患者代谢变化方面的作用。
{"title":"Efficacy of metformin drug in preventing metabolic syndrome associated with androgen deprivation therapy (ADT) in prostate cancer patients: A systematic review and meta-analysis.","authors":"Ibrahim Abdelnasar Yakout, Mohamed Mustafa Gallab, Daie AbdelRahman Mohamed, Hiba Hamdar, Sara I Ibrahim, Adham Mohamed, Abdelrahman Abdelshafi, Mohamed Abd-ElGawad","doi":"10.1053/j.seminoncol.2024.10.001","DOIUrl":"https://doi.org/10.1053/j.seminoncol.2024.10.001","url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer patients undergoing long-term (Androgen deprivation therapy) ADT will tend to have metabolic changes. Metabolic syndrome represents the accumulation of several medical conditions that significantly increase the risk of developing severe diseases like cardiovascular disorders, insulin resistance, and hyperglycemia. We are conducting this systematic review and meta-analysis to fill up the gap and to resolve the debate regarding the effectiveness of metformin in reducing metabolic syndrome associated with ADT in prostate cancer patients.</p><p><strong>Methods: </strong>We conducted the systematic review and meta-analysis according to the Handbook of Cochrane Systematic Review of Intervention and the PRISMA guidelines. We conducted the search process using the following databases: the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Scopus, and Web of Science. We selected the articles that fit within the following criteria, Randomized Controlled Trials (RCTs) and Cohort studies which evaluate the efficacy of metformin in reducing metabolic syndromes for prostate cancer patients undergoing androgen deprivation therapy (ADT). The efficacy of metformin in metabolic syndrome that resulted from using androgen deprivation therapy for prostate cancer patients was evaluated by the changes from baseline in Body Mass Index (BMI), waist circumference by cm, glycated hemoglobin (HbA1c), and blood pressure both systolic and diastolic. Revman software Version 5.4.1 was used to perform all statistical analyses.</p><p><strong>Results: </strong>Our search retrieved 781 records. Seven records were included in our study: 5 published randomized control clinical trials and 2 cohort studies and only 6 studies were included in the meta-analysis. For BMI the pooled effect estimates of 3 studies favored Metformin over placebo, but this is not a significant difference (MD = -0.9, P = 0.05), for systolic pressure the pooled effect estimates of 3 studies favored Metformin over placebo, but this is not a significantly different placebo (MD = -3.18, P = 0.22), for HBA1c the pooled effect estimates of 3 studies showed that no significant difference between placebo and metformin (MD = -0.01, P = 0.86)002E CONCLUSION: Despite the promising direction in some parameters, our findings underscore the need for further research to establish a clearer understanding of metformin's role in mitigating metabolic changes in prostate cancer patients undergoing ADT.</p>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142639712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Screening Adherence for Second Primary Malignancies in Breast Cancer Survivors: Behaviors, Facilitators, and Barriers to Enhance Quality Care. 乳腺癌幸存者坚持筛查第二原发性恶性肿瘤的情况:提高护理质量的行为、促进因素和障碍。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-28 DOI: 10.1053/j.seminoncol.2024.10.005
Fernanda Mesa-Chavez, Misael Salazar-Alejo, Cynthia Villarreal-Garza

Due to genetic, hormonal, and environmental factors, alongside increased life expectancy, breast cancer (BC) survivors have an increased risk of developing a second primary malignancy. Therefore, regular screening for other types of cancer is of utmost importance for their comprehensive care. This cross-sectional study evaluated BC survivors' compliance with cervical, lung, and colorectal cancer screening, and identified facilitators and barriers influencing adherence. Fifty-two BC survivors answered the study's survey. A total of three (6%) cases of second primary malignancies were self-reported. Cervical cancer screening was performed within the past 3 years among 37/50 (74%) eligible participants. Only 7/24 (29%) eligible participants underwent colorectal cancer screening within the last 10 years, including six colonoscopies and 1 occult blood test. No participant had an indication for lung cancer screening. The primary reason for noncompliance with both cervical and colorectal cancer screening was lack of physician's recommendation, accounting for 79% and 88% of cases, respectively. Nearly all participants (98%) affirmed that BC survivors should undergo screening for other types of cancer. Most (96%) stated that, if recommended by a physician, they would agree to undergo screening for other neoplasms. Even though most BC survivors acknowledged its importance, screening particularly for colorectal cancer exhibited suboptimal rates. Oncologists could play a crucial role in increasing cancer screening uptake by reminding patients of their corresponding recommendations to detect other types of cancer.

由于遗传、激素和环境因素以及预期寿命的延长,乳腺癌(BC)幸存者罹患第二种原发性恶性肿瘤的风险增加。因此,定期筛查其他类型的癌症对她们的全面护理至关重要。这项横断面研究评估了乳腺癌幸存者对宫颈癌、肺癌和结直肠癌筛查的依从性,并确定了影响依从性的促进因素和障碍。52 名 BC 幸存者回答了研究调查。自我报告的第二原发性恶性肿瘤病例共有三例(6%)。37/50(74%)名符合条件的参与者在过去三年内进行了宫颈癌筛查。只有 7/24 名(29%)符合条件的参与者在过去 10 年内接受了结肠直肠癌筛查,包括 6 次结肠镜检查和 1 次隐血试验。没有参与者有肺癌筛查指征。未接受宫颈癌和结肠直肠癌筛查的主要原因是缺乏医生建议,分别占 79% 和 88%。几乎所有的参与者(98%)都认为 BC 幸存者应该接受其他类型癌症的筛查。大多数人(96%)表示,如果医生推荐,他们会同意接受其他肿瘤筛查。尽管大多数 BC 幸存者都承认筛查的重要性,但筛查率尤其是结肠直肠癌筛查率并不理想。肿瘤学家可以通过提醒患者接受相应的建议来检测其他类型的癌症,从而在提高癌症筛查率方面发挥关键作用。
{"title":"Screening Adherence for Second Primary Malignancies in Breast Cancer Survivors: Behaviors, Facilitators, and Barriers to Enhance Quality Care.","authors":"Fernanda Mesa-Chavez, Misael Salazar-Alejo, Cynthia Villarreal-Garza","doi":"10.1053/j.seminoncol.2024.10.005","DOIUrl":"10.1053/j.seminoncol.2024.10.005","url":null,"abstract":"<p><p>Due to genetic, hormonal, and environmental factors, alongside increased life expectancy, breast cancer (BC) survivors have an increased risk of developing a second primary malignancy. Therefore, regular screening for other types of cancer is of utmost importance for their comprehensive care. This cross-sectional study evaluated BC survivors' compliance with cervical, lung, and colorectal cancer screening, and identified facilitators and barriers influencing adherence. Fifty-two BC survivors answered the study's survey. A total of three (6%) cases of second primary malignancies were self-reported. Cervical cancer screening was performed within the past 3 years among 37/50 (74%) eligible participants. Only 7/24 (29%) eligible participants underwent colorectal cancer screening within the last 10 years, including six colonoscopies and 1 occult blood test. No participant had an indication for lung cancer screening. The primary reason for noncompliance with both cervical and colorectal cancer screening was lack of physician's recommendation, accounting for 79% and 88% of cases, respectively. Nearly all participants (98%) affirmed that BC survivors should undergo screening for other types of cancer. Most (96%) stated that, if recommended by a physician, they would agree to undergo screening for other neoplasms. Even though most BC survivors acknowledged its importance, screening particularly for colorectal cancer exhibited suboptimal rates. Oncologists could play a crucial role in increasing cancer screening uptake by reminding patients of their corresponding recommendations to detect other types of cancer.</p>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deep Myometrial Infiltration leads to a measurable Inflammatory Response in Endometrial Cancer. A Prospective Observational Study. 深层子宫肌层浸润导致子宫内膜癌出现可测量的炎症反应。前瞻性观察研究。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-10-23 DOI: 10.1053/j.seminoncol.2024.10.002
Carlo Ronsini, Irene Iavarone, Eleonora Braca, Maria Giovanna Vastarella, Luigi Della Corte, Clorinda Vitale, Giada Andreoli, Elvira La Mantia, Luigi Cobellis, Pasquale de Franciscis

Backgrounds: This study aims to evaluate the correlation between inflammation indices, such as neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), platelet-lymphocyte ratio (PLR) and deep myometrial infiltration (≥50%) prospectively in patients with endometrial carcinoma, providing insights into the interaction between these parameters MATERIAL AND METHODS: A prospective observational cohort study was conducted at AOU Vanvitelli in Naples, Italy, from August 2023 to March 2024. Data from 161 patients undergoing surgery for endometrial cancer, including preoperative blood counts and histopathological information, were collected. Statistical analyses were performed using R software.

Results: After logistic regression, NLR and MLR showed a statistically significant association with deep myometrial infiltration (NLR log(OR) 0.15, P = .040; MLR log(OR) 0.30, P = .008). However, after multivariate logistic regression which included other risk factors such as grading, histotype, and MSI only NLR retained statistical significance, (Log(Or) 0.18, P = .031).

Conclusion: Our results demonstrate noticeable changes in inflammation indices associated with deep myometrial infiltration in endometrial carcinoma. Moreover, a correlation between NLR and deep myometrial infiltration exists regardless of microsatellite instability, histotype, and grading.

背景:本研究旨在前瞻性地评估子宫内膜癌患者的中性粒细胞-淋巴细胞比值(NLR)、单核细胞-淋巴细胞比值(MLR)、血小板-淋巴细胞比值(PLR)等炎症指数与子宫深部肌层浸润(≥50%)之间的相关性,从而深入了解这些参数之间的相互作用。 材料与方法:2023 年 8 月至 2024 年 3 月,意大利那不勒斯 AOU Vanvitelli 医院开展了一项前瞻性观察性队列研究:2023 年 8 月至 2024 年 3 月,意大利那不勒斯 AOU Vanvitelli 医院开展了一项前瞻性观察性队列研究。研究收集了 161 名接受子宫内膜癌手术患者的数据,包括术前血细胞计数和组织病理学信息。统计分析使用 R 软件进行:经过逻辑回归,NLR和MLR与子宫深部肌层浸润有显著的统计学关联(NLR log(OR) 0.15,P = .040;MLR log(OR) 0.30,P = .008)。然而,在包括分级、组织型和 MSI 等其他风险因素的多变量逻辑回归后,只有 NLR 仍具有统计学意义(Log(Or) 0.18,P = .031):我们的研究结果表明,子宫内膜癌的炎症指数发生了明显变化,这与子宫内膜癌的深部肌层浸润有关。此外,无论微卫星不稳定性、组织型和分级如何,NLR 与子宫深部肌层浸润之间都存在相关性。
{"title":"Deep Myometrial Infiltration leads to a measurable Inflammatory Response in Endometrial Cancer. A Prospective Observational Study.","authors":"Carlo Ronsini, Irene Iavarone, Eleonora Braca, Maria Giovanna Vastarella, Luigi Della Corte, Clorinda Vitale, Giada Andreoli, Elvira La Mantia, Luigi Cobellis, Pasquale de Franciscis","doi":"10.1053/j.seminoncol.2024.10.002","DOIUrl":"https://doi.org/10.1053/j.seminoncol.2024.10.002","url":null,"abstract":"<p><strong>Backgrounds: </strong>This study aims to evaluate the correlation between inflammation indices, such as neutrophil-lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), platelet-lymphocyte ratio (PLR) and deep myometrial infiltration (≥50%) prospectively in patients with endometrial carcinoma, providing insights into the interaction between these parameters MATERIAL AND METHODS: A prospective observational cohort study was conducted at AOU Vanvitelli in Naples, Italy, from August 2023 to March 2024. Data from 161 patients undergoing surgery for endometrial cancer, including preoperative blood counts and histopathological information, were collected. Statistical analyses were performed using R software.</p><p><strong>Results: </strong>After logistic regression, NLR and MLR showed a statistically significant association with deep myometrial infiltration (NLR log(OR) 0.15, P = .040; MLR log(OR) 0.30, P = .008). However, after multivariate logistic regression which included other risk factors such as grading, histotype, and MSI only NLR retained statistical significance, (Log(Or) 0.18, P = .031).</p><p><strong>Conclusion: </strong>Our results demonstrate noticeable changes in inflammation indices associated with deep myometrial infiltration in endometrial carcinoma. Moreover, a correlation between NLR and deep myometrial infiltration exists regardless of microsatellite instability, histotype, and grading.</p>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges. 埃塞俄比亚的结直肠癌:流行病学趋势、诊断和实验室能力以及挑战。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-09-21 DOI: 10.1053/j.seminoncol.2024.09.002
Gashaw Getaneh Dagnaw, Haileyesus Dejene

Colorectal cancer (CRC) refers to cancer that develops in the colon or rectum, parts of the large intestine. It ranks as the third most prevalent form of cancer globally. Colorectal cancer is responsible for the morbidity of millions and the loss of hundreds of thousands of lives worldwide although the incidence varies significantly depending on geographical location. In recent years, CRC has decreased in high-income countries due to technological advancements in diagnosis and treatment. However, there is an increased occurrence of CRC morbidity and mortality in low- and middle-income countries. Colorectal cancer is becoming an emerging public health concern in Ethiopia. We noticed that the incidence rates have been lower compared to more developed countries, but recent years have seen a noticeable increase. This rise is attributed to factors such as changes in diet, lifestyle, and an aging population. Common risk factors include dietary shifts towards processed foods and red meat, physical inactivity, obesity, smoking, and alcohol consumption. Unfortunately, in Ethiopia, screening programs for CRC are not widespread, and limited access to diagnostic facilities, lack of public awareness, and insufficient healthcare infrastructure contribute to late-stage diagnoses or left without diagnosis. Treatment options, including surgery, chemotherapy, and radiotherapy, are available but not uniformly accessible across the country, posing challenges for timely and effective treatment. Addressing colorectal cancer in Ethiopia requires a comprehensive approach to enhance public awareness, improve screening and early detection, expand treatment facilities, and train healthcare professionals to provide effective care.

大肠癌(CRC)是指发生在大肠的结肠或直肠部位的癌症。它在全球癌症发病率中排名第三。结肠直肠癌导致全球数百万人发病,数十万人丧生,但不同地理位置的发病率差异很大。近年来,由于诊断和治疗技术的进步,高收入国家的结直肠癌发病率有所下降。然而,在中低收入国家,结直肠癌的发病率和死亡率却在上升。在埃塞俄比亚,结直肠癌正成为一个新的公共卫生问题。我们注意到,与更发达的国家相比,埃塞俄比亚的发病率一直较低,但近年来发病率明显上升。这种上升可归因于饮食、生活方式的改变以及人口老龄化等因素。常见的风险因素包括饮食转向加工食品和红肉、缺乏运动、肥胖、吸烟和饮酒。遗憾的是,在埃塞俄比亚,儿童癌症筛查计划并不普及,诊断设施有限、公众意识缺乏以及医疗基础设施不足,都是导致晚期诊断或未确诊的原因。包括手术、化疗和放疗在内的治疗方案虽已提供,但在全国范围内并不普及,这给及时有效的治疗带来了挑战。要解决埃塞俄比亚的结直肠癌问题,需要采取全面的方法来提高公众意识,改善筛查和早期检测,扩大治疗设施,并培训医疗保健专业人员以提供有效的护理。
{"title":"Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges.","authors":"Gashaw Getaneh Dagnaw, Haileyesus Dejene","doi":"10.1053/j.seminoncol.2024.09.002","DOIUrl":"https://doi.org/10.1053/j.seminoncol.2024.09.002","url":null,"abstract":"<p><p>Colorectal cancer (CRC) refers to cancer that develops in the colon or rectum, parts of the large intestine. It ranks as the third most prevalent form of cancer globally. Colorectal cancer is responsible for the morbidity of millions and the loss of hundreds of thousands of lives worldwide although the incidence varies significantly depending on geographical location. In recent years, CRC has decreased in high-income countries due to technological advancements in diagnosis and treatment. However, there is an increased occurrence of CRC morbidity and mortality in low- and middle-income countries. Colorectal cancer is becoming an emerging public health concern in Ethiopia. We noticed that the incidence rates have been lower compared to more developed countries, but recent years have seen a noticeable increase. This rise is attributed to factors such as changes in diet, lifestyle, and an aging population. Common risk factors include dietary shifts towards processed foods and red meat, physical inactivity, obesity, smoking, and alcohol consumption. Unfortunately, in Ethiopia, screening programs for CRC are not widespread, and limited access to diagnostic facilities, lack of public awareness, and insufficient healthcare infrastructure contribute to late-stage diagnoses or left without diagnosis. Treatment options, including surgery, chemotherapy, and radiotherapy, are available but not uniformly accessible across the country, posing challenges for timely and effective treatment. Addressing colorectal cancer in Ethiopia requires a comprehensive approach to enhance public awareness, improve screening and early detection, expand treatment facilities, and train healthcare professionals to provide effective care.</p>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of neoadjuvant pembrolizumab in advanced melanoma. 新辅助治疗 pembrolizumab 在晚期黑色素瘤中的作用。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-09-21 DOI: 10.1053/j.seminoncol.2024.09.001
Maheen Amir, Zoha Ali Khan, Ayza Asad, Taha Gul Shaikh

Melanoma, a malignancy originating from melanocytes, poses a significant global health challenge, with approximately 325,000 cases and 57,000 deaths annually. Advanced melanoma (AM), categorized as stage III and IV, presents considerable treatment challenges due to its complex mutational landscape. Traditional treatment options have included checkpoint inhibitors and BRAF inhibitors, with pembrolizumab emerging as a promising agent. Approved by the FDA and EMA for various stages of melanoma, pembrolizumab is a humanized monoclonal antibody that blocks the PD-1/PD-L1 interaction, thereby enhancing immune system-mediated tumor eradication. This abstract discusses a recent phase 2 clinical trial evaluating the efficacy of neoadjuvant (presurgery) versus adjuvant (postsurgery) pembrolizumab treatment in resectable stage III or IV melanoma. The study, involving 313 patients across 90 US hospitals, found that neoadjuvant-adjuvant pembrolizumab significantly improved event-free survival (72%) compared to adjuvant-only treatment (49%) after 2 years. Treatment-related adverse events were consistent with known profiles, including fatigue, nausea, and diarrhea, without new severe adverse effects. No increase in surgery-related complications was observed with neoadjuvant treatment. These findings suggest that neoadjuvant pembrolizumab offers substantial benefits over adjuvant-only treatment, although further research is warranted. Future studies should focus on larger cohorts, diverse demographics, and extended follow-up to validate these results and potentially integrate neoadjuvant pembrolizumab into standard treatment protocols for advanced melanoma.

黑色素瘤是一种源自黑色素细胞的恶性肿瘤,每年约有 325,000 例病例和 57,000 例死亡病例,对全球健康构成重大挑战。晚期黑色素瘤(AM)分为 III 期和 IV 期,由于其突变情况复杂,给治疗带来了相当大的挑战。传统的治疗方案包括检查点抑制剂和BRAF抑制剂,而pembrolizumab则是一种很有前景的药物。Pembrolizumab 是一种人源化单克隆抗体,已获 FDA 和 EMA 批准用于治疗不同阶段的黑色素瘤,它能阻断 PD-1/PD-L1 的相互作用,从而增强免疫系统介导的肿瘤清除能力。本摘要讨论了最近的一项二期临床试验,该试验评估了新辅助(手术前)与辅助(手术后)pembrolizumab 治疗可切除 III 期或 IV 期黑色素瘤的疗效。这项研究涉及美国90家医院的313名患者,研究发现,与单纯辅助治疗(49%)相比,新辅助-辅助治疗pembrolizumab显著提高了患者2年后的无事件生存率(72%)。治疗相关不良事件与已知情况一致,包括疲劳、恶心和腹泻,没有出现新的严重不良反应。新辅助治疗并未增加手术相关并发症。这些研究结果表明,与单纯辅助治疗相比,新辅助治疗pembrolizumab具有很大的优势,但仍需进一步研究。未来的研究应侧重于更大的队列、不同的人口统计学特征和更长的随访时间,以验证这些结果,并有可能将新辅助pembrolizumab纳入晚期黑色素瘤的标准治疗方案中。
{"title":"Role of neoadjuvant pembrolizumab in advanced melanoma.","authors":"Maheen Amir, Zoha Ali Khan, Ayza Asad, Taha Gul Shaikh","doi":"10.1053/j.seminoncol.2024.09.001","DOIUrl":"https://doi.org/10.1053/j.seminoncol.2024.09.001","url":null,"abstract":"<p><p>Melanoma, a malignancy originating from melanocytes, poses a significant global health challenge, with approximately 325,000 cases and 57,000 deaths annually. Advanced melanoma (AM), categorized as stage III and IV, presents considerable treatment challenges due to its complex mutational landscape. Traditional treatment options have included checkpoint inhibitors and BRAF inhibitors, with pembrolizumab emerging as a promising agent. Approved by the FDA and EMA for various stages of melanoma, pembrolizumab is a humanized monoclonal antibody that blocks the PD-1/PD-L1 interaction, thereby enhancing immune system-mediated tumor eradication. This abstract discusses a recent phase 2 clinical trial evaluating the efficacy of neoadjuvant (presurgery) versus adjuvant (postsurgery) pembrolizumab treatment in resectable stage III or IV melanoma. The study, involving 313 patients across 90 US hospitals, found that neoadjuvant-adjuvant pembrolizumab significantly improved event-free survival (72%) compared to adjuvant-only treatment (49%) after 2 years. Treatment-related adverse events were consistent with known profiles, including fatigue, nausea, and diarrhea, without new severe adverse effects. No increase in surgery-related complications was observed with neoadjuvant treatment. These findings suggest that neoadjuvant pembrolizumab offers substantial benefits over adjuvant-only treatment, although further research is warranted. Future studies should focus on larger cohorts, diverse demographics, and extended follow-up to validate these results and potentially integrate neoadjuvant pembrolizumab into standard treatment protocols for advanced melanoma.</p>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated profile of tumor stage and mutational burden predicts disparate clinical responses to immune checkpoint inhibitors: A risk-benefit study. 肿瘤分期和突变负荷的综合概况可预测对免疫检查点抑制剂的不同临床反应:风险效益研究。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-09-16 DOI: 10.1053/j.seminoncol.2024.08.003
Ming Zheng

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, having demonstrated efficacy and leading to regulatory approvals of ICIs in cancers characterized by high tumor mutation burden (TMB). However, there remains a gap in determining their applicability and risk-benefit profile, across the broad spectrum of patients whose tumors harbor varying TMB levels across distinct tumor stages. By interrogating a large contemporary cohort comprised of 10,233 patients with a diagnosis of cancer across all tumor stages and TMB levels, this study revealed significantly improved overall survival (OS) following ICI therapy (P < .0001) in patients with a combination of ≥10 mut/Mb and stage IV disease. In contrast, ICI therapy is associated with markedly worse OS in patients with low TMB levels <10 mut/Mb and stages I, II, and III cancer. These findings highlight the critical interplay between TMB, tumor stage, and ICI treatment outcomes, underscoring the importance of integrating clinical and genetic characteristics in weighing the risk-benefit balance of ICI therapy. Although maximizing therapeutic benefits is crucial, it is equally important to identify and manage potential risks that may not be immediately apparent. This may require enrolling patients with less-severe or early-stage disease to enable long-term follow-up with effective clinical surveillance. By comprehensively evaluating the added benefit of improved treatment efficacy and the potential risk of adverse treatment outcome, a risk-benefit profile can optimize immunotherapy regimens, with profound implications for clinical decision-making and regulatory approvals of ICI.

免疫检查点抑制剂(ICIs)给癌症治疗带来了革命性的变化,在以高肿瘤突变负荷(TMB)为特征的癌症中显示出了疗效,并获得了监管部门的批准。然而,在确定这些药物的适用性和风险收益情况方面仍存在差距,这些药物适用于在不同肿瘤分期中肿瘤突变负荷水平各不相同的广大患者。本研究通过询问由 10,233 名确诊为癌症的所有肿瘤分期和 TMB 水平的患者组成的大型当代队列,发现 ICI 治疗可显著改善合并有 ≥10 突变/Mb 和 IV 期疾病的患者的总生存期(OS)(P < .0001)。相比之下,在 TMB 水平较低的患者中,ICI 治疗与明显较差的 OS 有关
{"title":"Integrated profile of tumor stage and mutational burden predicts disparate clinical responses to immune checkpoint inhibitors: A risk-benefit study.","authors":"Ming Zheng","doi":"10.1053/j.seminoncol.2024.08.003","DOIUrl":"https://doi.org/10.1053/j.seminoncol.2024.08.003","url":null,"abstract":"<p><p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, having demonstrated efficacy and leading to regulatory approvals of ICIs in cancers characterized by high tumor mutation burden (TMB). However, there remains a gap in determining their applicability and risk-benefit profile, across the broad spectrum of patients whose tumors harbor varying TMB levels across distinct tumor stages. By interrogating a large contemporary cohort comprised of 10,233 patients with a diagnosis of cancer across all tumor stages and TMB levels, this study revealed significantly improved overall survival (OS) following ICI therapy (P < .0001) in patients with a combination of ≥10 mut/Mb and stage IV disease. In contrast, ICI therapy is associated with markedly worse OS in patients with low TMB levels <10 mut/Mb and stages I, II, and III cancer. These findings highlight the critical interplay between TMB, tumor stage, and ICI treatment outcomes, underscoring the importance of integrating clinical and genetic characteristics in weighing the risk-benefit balance of ICI therapy. Although maximizing therapeutic benefits is crucial, it is equally important to identify and manage potential risks that may not be immediately apparent. This may require enrolling patients with less-severe or early-stage disease to enable long-term follow-up with effective clinical surveillance. By comprehensively evaluating the added benefit of improved treatment efficacy and the potential risk of adverse treatment outcome, a risk-benefit profile can optimize immunotherapy regimens, with profound implications for clinical decision-making and regulatory approvals of ICI.</p>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics. 解读美国监管框架:肿瘤生物仿制药与参考生物药的比较。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-09-04 DOI: 10.1053/j.seminoncol.2024.08.002
Ankita Tandulje, Priya Varpe, Purva Chaugule, Rajeev Singh Raghuvanshi, Saurabh Srivastava

Biological oncology agents are vital in cancer care, but their exorbitant expenses present obstacles for patients, families, healthcare professionals, and insurance providers. The advent of biosimilars represents a transformative solution, offering more affordable alternatives after the expiration of biologics patents. Biosimilar agents, similar to biological agents in structure, function, safety, and immunogenicity, enhance healthcare accessibility, improve outcomes, and reduce costs. Thus, the safety of biosimilars in clinical settings is of utmost importance. This review provides a detailed overview of the United States (US) regulatory framework for biosimilars along with a comparative analysis of Food and Drug Administration (FDA) approved biosimilar products. The FDA's "Biosimilar product information" database and "FDA's Purple Book" database were used to retrieve data on approved biosimilars and reference biologicals respectively. The study compares biosimilars and their reference products, examining their physiological action, pharmacokinetics, indications, adverse reactions, and immunogenicity test results and concludes that biosimilars do not have significant variations from their reference biologic products. This analysis will offer critical insights for medical practitioners, clinicians, and patients. It empowers stakeholders to make informed decisions, assessing whether biosimilars offer an equivalent level of safety compared to their reference products. Biosimilars are endorsed as credible substitutes for originator biologics, improving accessibility and affordability in cancer care, and benefiting patients and healthcare systems.

肿瘤生物制剂在癌症治疗中至关重要,但其高昂的费用给患者、家属、医疗保健专业人员和保险提供商造成了障碍。生物仿制药的出现代表了一种变革性的解决方案,为生物制剂专利到期后的患者提供了更实惠的替代品。生物仿制药在结构、功能、安全性和免疫原性方面与生物制剂相似,可提高医疗保健的可及性、改善疗效并降低成本。因此,生物仿制药在临床环境中的安全性至关重要。本综述详细概述了美国对生物仿制药的监管框架,并对美国食品和药物管理局(FDA)批准的生物仿制药产品进行了比较分析。本研究使用了 FDA 的 "生物仿制药产品信息 "数据库和 "FDA 紫皮书 "数据库,分别检索已获批准的生物仿制药和参比生物制剂的数据。研究比较了生物仿制药及其参照产品,考察了它们的生理作用、药代动力学、适应症、不良反应和免疫原性测试结果,得出结论认为生物仿制药与其参照生物制品没有明显差异。这项分析将为医疗从业人员、临床医生和患者提供重要的见解。它使利益相关者能够做出明智的决定,评估生物仿制药与其参照产品相比是否具有同等的安全性。生物仿制药被认可为原研生物制剂的可靠替代品,提高了癌症治疗的可及性和可负担性,使患者和医疗保健系统受益。
{"title":"Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics.","authors":"Ankita Tandulje, Priya Varpe, Purva Chaugule, Rajeev Singh Raghuvanshi, Saurabh Srivastava","doi":"10.1053/j.seminoncol.2024.08.002","DOIUrl":"https://doi.org/10.1053/j.seminoncol.2024.08.002","url":null,"abstract":"<p><p>Biological oncology agents are vital in cancer care, but their exorbitant expenses present obstacles for patients, families, healthcare professionals, and insurance providers. The advent of biosimilars represents a transformative solution, offering more affordable alternatives after the expiration of biologics patents. Biosimilar agents, similar to biological agents in structure, function, safety, and immunogenicity, enhance healthcare accessibility, improve outcomes, and reduce costs. Thus, the safety of biosimilars in clinical settings is of utmost importance. This review provides a detailed overview of the United States (US) regulatory framework for biosimilars along with a comparative analysis of Food and Drug Administration (FDA) approved biosimilar products. The FDA's \"Biosimilar product information\" database and \"FDA's Purple Book\" database were used to retrieve data on approved biosimilars and reference biologicals respectively. The study compares biosimilars and their reference products, examining their physiological action, pharmacokinetics, indications, adverse reactions, and immunogenicity test results and concludes that biosimilars do not have significant variations from their reference biologic products. This analysis will offer critical insights for medical practitioners, clinicians, and patients. It empowers stakeholders to make informed decisions, assessing whether biosimilars offer an equivalent level of safety compared to their reference products. Biosimilars are endorsed as credible substitutes for originator biologics, improving accessibility and affordability in cancer care, and benefiting patients and healthcare systems.</p>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy-A Systematic Review and Meta-Analysis. 接受化疗的癌症患者中的乙型肝炎病毒再激活--系统回顾和 Meta 分析。
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-08-26 DOI: 10.1053/j.seminoncol.2024.08.001
Natee Deepan, Soe Thiha Maung, Pakanat Decharatanachart, Roongruedee Chaiteerakij

Hepatitis B virus (HBV) reactivation is a critical concern for patients with a diagnosis of cancer receiving chemotherapy worldwide. Our aim was to assess the rate of HBV reactivation during chemotherapy globally. We systematically reviewed PubMed, Embase, Scopus, and Google Scholar databases for chemotherapy-related HBV reactivation studies from inception until July 2023. A random-effects model was used to estimate the pooled reactivation rate. Total 86 studies involving 21,297 patients were included, comprising 62 and 24 studies from Eastern and Western regions. Pooled results indicated a 9% reactivation rate (95%CI: 7%-13%, I2 = 95%). Reactivation rates were 10% (95%CI: 7%-14%, I2 = 92%) for hematological malignancies and 5% (95%CI: 3%-9%, I2 = 94%) for solid tumors. Presence of HBV DNA, HBeAg, and HBsAg were correlated with reactivation rates of 29% (95%CI: 10%-60%, I2 = 91%), 23% (95%CI: 14%-36%, I2 = 78%), and 15% (95%CI: 11%-20%, I2 = 90%), respectively. For patients with positive anti-HBe Ab, anti-HBc, and anti-HBs Ab serology, pooled reactivation rates were 7% (95%CI: 3%-14%, I2 = 81%), 4% (95%CI: 3%-7%, I2 = 85%), and 3% (95%CI: 2%-6%, I2 = 80%), respectively. With antiviral prophylaxis, reactivation rates were 1% (95%CI: 0%-17%, I2 = 59%), 1% (95%CI: 0%-5%, I2 = 0%), 4% (95%CI: 2%-9%, I2 = 85%), and 6% (95%CI: 3%-12%, I2 = 32%) for patients receiving tenofovir, entecavir, lamivudine, and telbivudine, respectively. Patients with a diagnosis of cancer undergoing chemotherapy face increased risk of HBV reactivation. This analysis raises public awareness and serves as a resource for future clinical trials.

乙型肝炎病毒(HBV)再活化是全球接受化疗的癌症患者所关心的一个重要问题。我们的目的是评估全球化疗期间的 HBV 再激活率。我们系统地查阅了 PubMed、Embase、Scopus 和 Google Scholar 数据库中从开始到 2023 年 7 月与化疗相关的 HBV 再激活研究。我们采用随机效应模型来估算汇总的再活率。共纳入 86 项研究,涉及 21,297 名患者,其中 62 项研究来自东部地区,24 项研究来自西部地区。汇总结果显示,重新激活率为 9%(95%CI:7%-13%,I2 = 95%)。血液恶性肿瘤的再活率为 10%(95%CI:7%-14%,I2 = 92%),实体瘤的再活率为 5%(95%CI:3%-9%,I2 = 94%)。HBV DNA、HBeAg 和 HBsAg 的存在分别与 29%(95%CI:10%-60%,I2 = 91%)、23%(95%CI:14%-36%,I2 = 78%)和 15%(95%CI:11%-20%,I2 = 90%)的再活率相关。对于抗-HBe Ab、抗-HBc 和抗-HBs Ab 血清学阳性的患者,汇总的再活率分别为 7% (95%CI: 3%-14%, I2 = 81%)、4% (95%CI: 3%-7%, I2 = 85%) 和 3% (95%CI: 2%-6%, I2 = 80%)。接受抗病毒预防治疗后,接受替诺福韦、恩替卡韦、拉米夫定和替比夫定治疗的患者的再活率分别为1%(95%CI:0%-17%,I2 = 59%)、1%(95%CI:0%-5%,I2 = 0%)、4%(95%CI:2%-9%,I2 = 85%)和6%(95%CI:3%-12%,I2 = 32%)。确诊癌症并接受化疗的患者面临着更高的 HBV 再激活风险。这项分析提高了公众的认识,并为未来的临床试验提供了资源。
{"title":"Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy-A Systematic Review and Meta-Analysis.","authors":"Natee Deepan, Soe Thiha Maung, Pakanat Decharatanachart, Roongruedee Chaiteerakij","doi":"10.1053/j.seminoncol.2024.08.001","DOIUrl":"https://doi.org/10.1053/j.seminoncol.2024.08.001","url":null,"abstract":"<p><p>Hepatitis B virus (HBV) reactivation is a critical concern for patients with a diagnosis of cancer receiving chemotherapy worldwide. Our aim was to assess the rate of HBV reactivation during chemotherapy globally. We systematically reviewed PubMed, Embase, Scopus, and Google Scholar databases for chemotherapy-related HBV reactivation studies from inception until July 2023. A random-effects model was used to estimate the pooled reactivation rate. Total 86 studies involving 21,297 patients were included, comprising 62 and 24 studies from Eastern and Western regions. Pooled results indicated a 9% reactivation rate (95%CI: 7%-13%, I<sup>2</sup> = 95%). Reactivation rates were 10% (95%CI: 7%-14%, I<sup>2</sup> = 92%) for hematological malignancies and 5% (95%CI: 3%-9%, I<sup>2</sup> = 94%) for solid tumors. Presence of HBV DNA, HBeAg, and HBsAg were correlated with reactivation rates of 29% (95%CI: 10%-60%, I<sup>2</sup> = 91%), 23% (95%CI: 14%-36%, I<sup>2</sup> = 78%), and 15% (95%CI: 11%-20%, I<sup>2</sup> = 90%), respectively. For patients with positive anti-HBe Ab, anti-HBc, and anti-HBs Ab serology, pooled reactivation rates were 7% (95%CI: 3%-14%, I<sup>2</sup> = 81%), 4% (95%CI: 3%-7%, I<sup>2</sup> = 85%), and 3% (95%CI: 2%-6%, I<sup>2</sup> = 80%), respectively. With antiviral prophylaxis, reactivation rates were 1% (95%CI: 0%-17%, I<sup>2</sup> = 59%), 1% (95%CI: 0%-5%, I<sup>2</sup> = 0%), 4% (95%CI: 2%-9%, I<sup>2</sup> = 85%), and 6% (95%CI: 3%-12%, I<sup>2</sup> = 32%) for patients receiving tenofovir, entecavir, lamivudine, and telbivudine, respectively. Patients with a diagnosis of cancer undergoing chemotherapy face increased risk of HBV reactivation. This analysis raises public awareness and serves as a resource for future clinical trials.</p>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142626804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of PSA responses and changes in the rate of tumor growth (g-rate) with immune checkpoint inhibitors in US Veterans with prostate cancer 评估美国退伍军人前列腺癌患者对免疫检查点抑制剂的 PSA 反应和肿瘤生长率的变化
IF 3 3区 医学 Q2 ONCOLOGY Pub Date : 2024-06-01 DOI: 10.1053/j.seminoncol.2024.04.002

We examined data from US Veterans with prostate cancer (PC) to assess disease response to immune checkpoint inhibitors (ICI) as monotherapy or combined with abiraterone or enzalutamide to assess ICI efficacy in the real-world. We queried the VA corporate data warehouse (CDW) to identify Veterans with a diagnosis of PC who received ICI for any malignancy and had ≥1 PSA measurement while receiving ICI. To evaluate ICI monotherapy, we restricted analysis to Veterans who had not received LHRH agonists/antagonists, PC-directed medical therapy, or radiation/extirpative surgery of the bladder/prostate within and preceding the duration of ICI administration. For ICI combination analysis, we identified Veterans who received abiraterone or enzalutamide for PC while on ICI. We calculated rates of tumor (PSA) growth (g-rates), comparing them to a 1:2 matched reference cohort. We identified 787 Veterans with PC and ≥1 PSA measurement while receiving an ICI. Median duration of ICI therapy was 155 days. 223 Veterans received ICI monotherapy, with only 17(8%) having a reduction in PSA (median decline = 43%). 12 (5%) had PSA declines >30% (PSA30) which included 6 (3%) who had PSA reductions greater than 50% (PSA50). Median g-rates for ICI plus abiraterone (n = 20) or enzalutamide (n = 31) were 0.000689/d−1 and 0.002819/d−1, respectively, and were statistically insignificant compared to g-rates of matched cohorts receiving abiraterone (g = 0.000925/d−1, P = 0.73) or enzalutamide (g = 0.001929/d−1, P = 0.58) alone. Our data align with clinical trial data in PC, demonstrating limited benefit from ICI monotherapy and predicting no survival benefit from simultaneous abiraterone or enzalutamide with an ICI using g-rate.

背景:免疫检查点抑制剂(PD1/PDL1 抑制剂;ICI)治疗前列腺癌(PC)的价值有限。我们研究了患有前列腺癌的美国退伍军人的数据,以评估他们对 ICIs 单药治疗或与阿比特龙或恩杂鲁胺联合治疗的疾病反应。我们将结果与参考数据集进行了比较,以评估 ICI 在现实世界中的疗效。方法:我们查询了退伍军人事务部的企业数据仓库 (CDW),以确定诊断为 PC 的退伍军人,这些退伍军人因任何恶性肿瘤接受过 ICI 治疗,且在接受 ICI 治疗期间 PSA 测量次数≥ 1 次。为评估 ICI 单药治疗,我们将分析对象限定为在接受 ICI 治疗期间及之前未接受过 LHRH 激动剂/拮抗剂、PC 导向药物治疗或膀胱/前列腺放射/外切手术的退伍军人。对于 ICI 组合分析,我们确定了在服用 ICI 期间接受阿比特龙或恩杂鲁胺治疗 PC 的退伍军人。我们计算了肿瘤(PSA)生长率(g-rates),并将其与 1:2 匹配的参照队列进行了比较。结果:我们发现了 787 名退伍军人在接受 ICI 治疗期间患有 PC 且 PSA 测量次数≥ 1 次。ICI 治疗的中位持续时间为 155 天。223 名退伍军人接受了 ICI 单药治疗,其中只有 17 人(8%)的 PSA 有所下降(中位数降幅=43%)。12人(5%)的PSA下降幅度大于30%(PSA30),其中6人(3%)的PSA下降幅度大于50%(PSA50)。ICI 加阿比特龙(n=20)或恩扎鲁胺(n=31)的中位 g 比率分别为 0.000689/d -1 和 0.002819/d-1,与单独接受阿比特龙(g=0.000925/d-1,p=0.73)或恩扎鲁胺(g=0.001929/d-1,p=0.58)的匹配队列的 g 比率相比,统计学上并不显著。结论我们的数据与PC的临床试验数据相吻合,结果表明ICI单药治疗的获益有限,而使用g-rate预测阿比特龙或恩扎鲁胺与ICI同时用药不会带来生存获益。我们证明了估算g-率和我们的参考数据库在解决具有挑战性的临床问题和辅助药物开发方面的价值。
{"title":"Assessment of PSA responses and changes in the rate of tumor growth (g-rate) with immune checkpoint inhibitors in US Veterans with prostate cancer","authors":"","doi":"10.1053/j.seminoncol.2024.04.002","DOIUrl":"10.1053/j.seminoncol.2024.04.002","url":null,"abstract":"<div><p><span><span><span>We examined data from US Veterans with prostate cancer<span> (PC) to assess disease response to immune checkpoint inhibitors (ICI) as </span></span>monotherapy<span> or combined with abiraterone or </span></span>enzalutamide to assess ICI efficacy in the real-world. We queried the VA corporate data warehouse (CDW) to identify Veterans with a diagnosis of PC who received ICI for any malignancy and had ≥1 PSA measurement while receiving ICI. To evaluate ICI monotherapy, we restricted analysis to Veterans who had not received LHRH agonists/antagonists, PC-directed medical therapy, or radiation/extirpative surgery of the bladder/prostate within and preceding the duration of ICI administration. For ICI combination analysis, we identified Veterans who received abiraterone or enzalutamide for PC while on ICI. We calculated rates of tumor (PSA) growth (</span><strong><em>g</em></strong>-rates), comparing them to a 1:2 matched reference cohort. We identified 787 Veterans with PC and ≥1 PSA measurement while receiving an ICI. Median duration of ICI therapy was 155 days. 223 Veterans received ICI monotherapy, with only 17(8%) having a reduction in PSA (median decline = 43%). 12 (5%) had PSA declines &gt;30% (PSA30) which included 6 (3%) who had PSA reductions greater than 50% (PSA50). Median <strong><em>g</em></strong>-rates for ICI plus abiraterone (n = 20) or enzalutamide (n = 31) were 0.000689/d<sup>−1</sup> and 0.002819/d<sup>−1</sup>, respectively, and were statistically insignificant compared to <strong><em>g</em></strong>-rates of matched cohorts receiving abiraterone (<strong><em>g</em></strong> = 0.000925/d<sup>−1</sup>, <em>P</em> = 0.73) or enzalutamide (<strong><em>g</em></strong> = 0.001929/d<sup>−1</sup>, <em>P</em><span> = 0.58) alone. Our data align with clinical trial data in PC, demonstrating limited benefit from ICI monotherapy and predicting no survival benefit from simultaneous abiraterone or enzalutamide with an ICI using </span><strong><em>g</em></strong>-rate.</p></div>","PeriodicalId":21750,"journal":{"name":"Seminars in oncology","volume":"51 3","pages":"Pages 59-68"},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141029034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Seminars in oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1